Back to Journals » Cancer Management and Research » Volume 9

Standard of care and direct medical costs of the treatment of chronic lymphocytic leukemia among the adult population in Ukraine, Russia, and Kazakhstan: data from the LEUKOSPECT study

Authors Vasylyev A, Molostvova V, Rebrov BA, Makarova J, Zaritskey A, Ptushkin V, Ramazanova R, Popovych Y, Tsyapka O, Pashanov E

Received 19 April 2017

Accepted for publication 23 June 2017

Published 7 September 2017 Volume 2017:9 Pages 387—395

DOI https://doi.org/10.2147/CMAR.S139915

Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Dr Akshita Wason

Peer reviewer comments 2

Editor who approved publication: Professor Nakshatri


Averyan Vasylyev,1 Valentina Molostvova,2 Boris A Rebrov,3 Janina Makarova,4 Andrey Zaritskey,5 Vadim Ptushkin,6 Raigul Ramazanova,7 Yuriy Popovych,8 Orest Tsyapka,9 Evgeny Pashanov10

1CIS Medical, GlaxoSmithKline, Kiev, Ukraine; 2Regional Clinical Hospital No. 1, Khabarovsk, Russia; 3Lugansk Regional Clinical Hospital, Lugansk, Ukraine; 4Russia Medical Department, GlaxoSmithKline, Moscow, Russia; 5Oncohaematology Department, Almazov Federal Heart, Blood and Endocrinology Centre, Saint Petersburg, Russia; 6S.P. Botkin Hospital, Moscow, Russia; 7Kazakh Scientific Research Institute of Oncology and Radiology, Almaty, Kazakhstan; 8Zakarpatskaya Regional Clinical Hospital, Zakarpatskaya, Ukraine; 9Institute of Blood Pathology and Transfusion Medicine, Lviv, Ukraine; 10Novartis Pharma LLC, Moscow, Russia

Purpose: The LEUKOSPECT study aimed to describe health service utilization and to estimate the direct medical costs (DMCs) of chronic lymphocytic leukemia (CLL) in 2013 in the adult population of three post-Soviet countries – Russia, Ukraine, and Kazakhstan. As oncologic medical care is provided by federal state-owned, specialized medical institutions, the cost estimation in this study primarily informs from a state budget perspective. Patients’ contributions to medical costs were not included in the cost evaluation.
Patients and methods: This was a multinational, multicenter, retrospective study conducted in eight specialized centers (four in Russia, three in Ukraine, and one in Kazakhstan). The investigators captured data from the medical documents of all adult patients with an established CLL diagnosis before December 31, 2013, and who made at least one visit to their respective center between January 1 and December 31, 2013.
Results: A total of 319 adult CLL patients were enrolled (124 in Kazakhstan, 106 in Russia, and 89 in Ukraine). In 2013, the DMCs of CLL management (without CLL therapy) were €215.40 in Kazakhstan, €1,342.20 in Russia, and €13,260.70 in Ukraine. Hospitalizations formed the largest proportion of total cost: 18.1%, 23.1%, and 40.4%, respectively. The mean cost of CLL medical treatment was €13,580.60 (Russia), €399.40 (Kazakhstan), and €7,453.00 (Ukraine).
Conclusion: CLL treatment standards varied across the selected countries; higher usage of biologic therapy was noted in Russia. Future research is needed to assess DMCs which include CLL treatment, which is another essential factor contributing to CLL DMCs.

Keywords: chronic lymphocytic leukemia, standard of care, direct medical cost, Russia, Ukraine, Kazakhstan
 

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]